Treatment Of Mastitis In Cattle Research Articles

Alternative treatment methods for bovine mastitis: prospects and limitations (review)

Mastitis remains the most common problem of dairy industry despite the preventive measures and treatment schemes being developed. Antibacterial drugs remain first line agents for therapy of the mammary gland inflammatory diseases in animals. Taking into account the risks associated with antibiotic therapy, such as decreased drug effectiveness due to occurrence of bacterial resistant strains, food safety issues, environmental impact and restrictions on the use of antibacterial drugs in veterinary medicine, an increasing number of scientific studies are addressing new therapeutic agents that can serve as an alternative to conventional therapy. The aim of this review is to give an idea of currently available literature data on alternative methods for the prevention and treatment of mastitis in cattle that are not associated with antibiotics. In general, a significant number of in vitro studies aimed at finding new effective and safe drugs are yielding promising results. This review describes the following alternative remedies: probiotics, bacteriocins, bacteriophages, phage enzymes (endolysins), nanoparticles, plant extracts, essential oils and immunobiological agents (vaccines). Understanding the mechanisms of their action will allow recommending the best treatment option for mastitis in each specific case. These treatment methods can potentially reduce use of antibiotics and increase animal productivity, however more in vivo studies are needed to prove the effectiveness of antibiotics used directly in the conditions of farm settings.

An integrated approach to the prevention and treatment of mastitis in cattle

This article presents the results of research on the effectiveness of preventive and therapeutic measures for mastitis in cattle. In modern conditions, in the farms of the Smolensk region, the disease of large cattle (cows) with mastitis is an urgent problem. In this regard, the subject of our research was the work on the search and application of new most effective means for the prevention and treatment of breast disease in lactating cows. The object of research was cattle. The work was carried out in the conditions of a farm in the Smolensk region. In order to implement a comprehensive approach to the diagnosis, prevention and therapy of cattle in the household, the situation was first studied by suit.

STUDY OF ACUTE TOXICITY OF A NEW VETERINARY DRUG FOR INTTRAMMARY INTRODUCTION

Preclinical studies of veterinary medicinal products are important and compulsory studies in the development of new dosage forms. The aim of preclinical research is to determine the toxic effect and therapeutic efficacy of the test substance-the future dosage form, its effect on the body's basic systems, as well as the identification of possible side effects. This work is part of the research on the development of the composition and technology of the veterinary drug - a solution for intramammary application, conventionally called "Argocide", intended for the treatment of mastitis in cattle. A study of the acute toxicity of the intramammary veterinary drug was carried out in experiments on white rats of both sexes, according to the requirements for potential medicines. The establishment of the value of the average lethal dose (LD50) of the veterinary drug "Argocide" with intramuscular single administration to white mature rats is impossible due to the absence of animal death even when the drug is administered at doses exceeding 5.0 ml/kg. This experiment allows the veterinary preparation "Argocide" to be classified as practically non-toxic compounds (V class). The analysis of the results of the conducted studies indicates the relative harmlessness of the potential drug for veterinary medicine and allows us to foresee that the "Argocide" preparation can be classified as low-risk substances, which justifies the expediency of its further study and introduction into practice.

ВИВЧЕННЯ ГОСТРОЇ ТОКСИЧНОСТІ ПРЕПАРАТУ АРГОЦИД ПРИ ВНУТРІШНЬООЧЕРЕВИННОМУ ВВЕДЕННІ

Мета роботи. Вивчення гострої токсичності ветеринарного препарату Аргоцид, розчин для інтрацистернального введення, при внутрішньоочеревинному введенні статевозрілим білим щурам.Матеріали і методи. Об'єктом дослідження були серії препарату Аргоцид, який містить цитрат срібла, D- пантенол та L- аргінін, призначений для лікування субклінічного маститу великої рогатої худоби. Дослідження гострої токсичності тест-зразків препарату Аргоцид проводили у дослідах на білих нелінійних статевозрілих щурах обох статей, віповідно до вимог, що висувають до потенційних ліків. Випробування проведені при внутрішньочеревному введенні препарату в різних дозах – від 2,0 до 6,3 мл / кг. Статистична обробка даних була виконана з використанням t-критерію Стьюдента. Для статистичної обробки даних використано програму MS Excel.Результати й обговорення. У результаті дослідження гострої токсичності препарату Аргоцид встановлено, що інтегральні показники життєдіяльності тварин – маса та температура тіла не зазнавали суттєвих індивідуальних змін вподовж 14 діб спостереження після одноразового внутрішньоочеревинного введення. При досліджені дози препарату у діапазоні від 1,58 мл/кг маси тіла тварини до 5,0 мл/кг визначено, що жодного випадку загибелі тварин не зареєстровано за внутрішньоочеревинного введення препарату у будь-якій дозі. При застосуванні препарату у дозах 2,5 мл/кг та вище у тварин проявилися клінічні ознаки інтоксикації відразу після введення препарату, що може бути пов’язано з подразненням очеревини. Через 3 доби після внутрішньоочеревинного застосування Аргоциду жодних клінічних ознак інтоксикації не спостерігали.Висновки. Аналіз отриманих даних дозволяє віднести препарат Аргоцид, розчин для інтрацистернального введення за ступенем небезпеки до відносно нешкідливих препаратів (VI клас) оскільки середня летальна доза перевищує 3,0 мл/кг маси тіла тварини за внутрішньоочеревинного введення.

The usage of veterinary antibacterial drugs for mastitis in cattle in Norway and Sweden during 1990–1997

The prescribing patterns and annual incidence of use of antibacterial drugs for the treatment of mastitis in cattle in Norway and Sweden during the period 1990–1997 were estimated from drug wholesaler statistics. Although the drugs included in this study are also used in other species and/or other indications, mastitis in cattle is by far the most-common indication for their use. We used these sales figures to evaluate trends in the use of antibacterial drugs and changes in the incidence of treatment in bovine mastitis in Norway and Sweden. To facilitate comparisons (correcting for differences in activity and dosage) between the relative proportions of antibacterial drugs used in bovine mastitis, we introduced defined daily dose cow (DDDcow) as unit of measurement. Tentative DDDcow for the various injectable drugs were derived from doses recommended in Norway and Sweden. For intramammary drugs administered in the form of single-dose applicators, one applicator was defined as the DDDcow. The prescribing patterns of antibacterial drugs in bovine mastitis in Norway and Sweden during the study period seemed to be influenced by treatment policies, substances and formulations approved and treatment cost; length of the withdrawal period also seemed to play a role.

Vaccine Treatment of Mastitis in Cattle

Vaccine Treatment of Mastitis in Cattle